Optimind looks to accelerate the adoption of the MindSetting TRIP Protocol for ketamine-assisted therapy and other psychedelic enhanced psychotherapy modalities.
Toronto, Ontario (Newsfile Corp. - September
The Globe and Mail Jameson Berkow Published March 2, 2021
Moha El-Jaw/iStockPhoto / Getty Images
Could the burgeoning psychedelics sector end up spawning a major stock rally that could dwarf the cannabis-driven market mayhem of the past decade?
According to Maruf Raza, a partner and national director of public companies at MNP LLP in Toronto, “From a market perspective, you could argue the blue-sky opportunity for psychedelics is far, far greater [than for cannabis].”
Mr. Raza is part of a growing group of market watchers expecting vast sums of money to pour into companies studying psilocybin, ketamine, LSD and other so-called “hard drugs” for medical purposes. But because the nascent sector is largely organized around disrupting the global anti-depressant market, which is worth tens of billions of dollars annually to pharmaceutical giants, investors see less policy risk.